The human serpin proteinase inhibitor-9 self-associates at physiological temperatures

Protein Science

Volumn 13, Issue 7, 2004, Pages 1859-1864

  Benning, Lauren N ^a   Whisstock, James C ^a   Sun, Jiuru ^a   Bird, Phillip I ^a   Bottomley, Stephen P ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Aggregation; Conformational disease; Protein misfolding; Serpin

Indexed keywords

FLUORESCENT DYE; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR 9; THIOFLAVINE; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATIONAL TRANSITION; ELECTRON MICROSCOPY; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; GENE MUTATION; HUMAN; HUMAN CELL; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN STRUCTURE; SPECTROSCOPY; WILD TYPE;

DEMENTIA; EMPHYSEMA; HUMANS; MICROSCOPY, ELECTRON; MULTIPROTEIN COMPLEXES; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; SERPINS; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THROMBOSIS;

EID: 3042621286     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.04715304     Document Type: Article

References (55)

1. Annand, R.R., Dahlen, J.R., Sprecher, C.A., De Dreu, P., Foster, D.C., Mankovich, J.A., Talanian, R.V., Kisiel, W., and Giegel, D.A. 1999. Caspase-1 (interleukin-1-β-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. Biochem. J. 342: 655-665.
2. Bird, C.H., Sutton, V.R., Sun, J., Hirst, C.E., Novak, A., Kumar, S., Trapani, J.A., and Bird, P.I. 1998. Selective regulation of apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol. Cell. Biol. 18: 6387-6398.
3. Bladergroen, B.A., Strik, M.C., Bovenschen, N., van Berkum, O., Scheffer, G.L., Meijer, C.J., Hack, C.E., and Kummer, J.A. 2001. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J. Immunol. 166: 3218-3225.
4. Bottomley, S.P. and Chang, W.-S. 1997. The effect of reactive centre loop length upon serpin polymerisation. Biochem. Biophys. Res. Comm. 241: 264-269.
5. Bottomley, S.P., Hopkins, P.C., and Whisstock, J.C. 1998. α1-antitrypsin polymerisation can occur by both loop A and C sheet mechanisms. Biochem. Biophys. Res. Comm. 251: 1-5.
6. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C.M., and Stefani, M. 2002. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511.
7. Buzza, M.S., Hirst, C.E., Bird, C.H., Hosking, P., McKendrick, J., and Bird, P.I. 2001. The granzyme B inhibitor, PI-9, is present in endothelial and mesothelial cells, suggesting that it protects bystander cells during immune responses. Cell. Immunol. 210: 21-29.
8. Cabrita, L.D. and Bottomley, S.P. 2004. How do proteins avoid becoming too stable? Biophysical studies into metastable proteins. Eur. Biophys. J. 33: 83-88.
9. Carrell, R.W., Pemberton, P.A., and Boswell, D.R. 1987. The serpins: Evolution and adaptation in a family of protease inhibitors. Cold Spring Harbor Symp. Quant. Biol. 52: 527-535.
10. Chang, W.S.W., Whisstock, J., Hopkins, P.C.R., Lesk, A.M., Carrell, R.W., and Wardell, M.R. 1997. Importance of the release of strand 1c to the polymerization mechanism of inhibitory serpins. Protein Sci. 6: 89-98.
11. Chow, M.K., Lomas, D.A., and Bottomley, S.P. 2004a. Promiscuous β-strand interactions and the conformational diseases. Curr. Med. Chem. 11: 491-499.
12. Chow, M.K., Paulson, H.L., and Bottomley, S.P. 2004b. Destabilization of a non-pathological variant of ataxin-3 results in fibrillogenesis via a partially folded intermediate: A model for misfolding in polyglutamine disease. J. Mol. Biol. 335: 333-341.
13. Dafforn, T.R., Mahadeva, R., Elliott, P.R., Sivasothy, P., and Lomas, D.A. 1999. A kinetic mechanism for the polymerization of α1-antitrypsin. J. Biol. Chem. 274: 9548-9555.
14. Dafforn, T.R., Pike, R.N., and Bottomley, S.P. 2004. Physical characterization of serpin conformations. Methods 32: 150-158.
15. Devlin, G.L., Chow, M.K., Howlett, G.J., and Bottomley, S.P. 2002. Acid denaturation of α(1)-antitrypsin: Characterization of a novel mechanism of serpin polymerization. J. Mol. Biol. 324: 859-870.
16. Devlin, G.L., Carver, J.A., and Bottomley, S.P. 2003. The selective inhibition of serpin aggregation by the molecular chaperone, α-crystallin, indicates a nucleation-dependent specificity. J. Biol. Chem. 278: 48644-48650.
17. Dunstone, M.A., Dai, W., Whisstock, J.C., Rossjohn, J., Pike, R.N., Feil, S.C., Le Bonniec, B.F., Parker, M.W., and Bottomley, S.P. 2000. Cleaved antitrypsin polymers at atomic resolution. Protein Sci. 9: 417-420.
18. Huntington, J.A., Pannu, N.S., Hazes, B., Read, R.J., Lomas, D.A., and Carrell, R.W. 1999. A 2.6 Å structure of a serpin polymer and implications for conformational disease. J. Mol. Biol. 293: 449-455.
19. Huntington, J.A., Read, R.J., and Carrell, R.W. 2000. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407: 923-926.
20. Im, H., Seo, E.J., and Yu, M.H. 1999. Metastability in the inhibitory mechanism of human α1-antitrypsin. J. Biol. Chem. 274: 11072-11077.
21. James, E.L. and Bottomley, S.P. 1998. The mechanism of α 1-antitrypsin polymerization probed by fluorescence spectroscopy. Arch. Biochem. Biophys. 356: 296-300.
22. Kang, H.A., Lee, K.N., and Yu, M.H. 1997. Folding and stability of the Z and S(iiyama) genetic variants of human α1-antitrypsin. J. Biol. Chem. 272: 510-516.
23. Kaslik, G., Patthy, A., Balint, M., and Graf, L. 1995. Trypsin complexed with α 1-proteinase inhibitor has an increased structural flexibility. FEBS Lett. 370: 179-183.
24. Kim, D. and Yu, M.H. 1996. Folding pathway of human α 1-antitrypsin: Characterization of an intermediate that is active but prone to aggregation. Biochem. Biophys. Res. Commun. 226: 378-384.
25. Lashuel, H.A., Wurth, C., Woo, L., and Kelly, J.W. 1999. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 38: 13560-13573.
26. Lee, C., Park, S.H., Lee, M.Y., and Yu, M.H. 2000. Regulation of protein function by native metastability. Proc. Natl. Acad. Sci. 97: 7727-7731.
27. Lomas, D.A., Evans, D.L., Finch, J.T., and Carrell, R.W. 1992. The mechanism of Z α 1-antitrypsin accumulation in the liver. Nature 357: 605-607.
28. Lomas, D.A., Evans, D.L., Stone, S.R., Chang, W.S., and Carrell, R.W. 1993. Effect of the Z mutation on the physical and inhibitory properties of α 1-antitrypsin. Biochemistry 32: 500-508.
29. Lomas, D.A., Elliott, P.R., Sidhar, S.K., Foreman, R.C., Finch, J.T., Cox, D.W., Whisstock, J.C., and Carrell, R.W. 1995. α 1-antitrypsin Mmalton (Phe52-deleted) forms loop-sheet polymers in vivo. Evidence for the C sheet mechanism of polymerization. J. Biol. Chem. 270: 16864-16870.
30. Mahadeva, R., Dafforn, T.R., Carrell, R.W., and Lomas, D.A. 2002. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z α(1)-antitrypsin- related cirrhosis. J. Biol. Chem. 277: 6771-6774.
31. Marszal, E., Danino, D., and Shrake, A. 2003. A novel mode of polymerization of α1-proteinase inhibitor. J. Biol. Chem. 278: 19611-19618.
32. Mikus, P. and Ny, T. 1996. Intracellular polymerization of the serpin plasminogen activator inhibitor type 2. J. Biol. Chem. 271: 10048-10053.
33. Mikus, P., Urano, T., Liljestrom, P., and Ny, T. 1993. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. Eur. J. Biochem. 218: 1071-1082.
34. Pace, C.N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. 1995. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4: 2411-2423.
35. Potempa, J., Korzus, E., and Travis, J. 1994. The serpin superfamily of proteinase inhibitors: Structure, function, and regulation. J. Biol. Chem. 269: 15957-15960.
36. Remold-O'Donnell, E. 1993. The ovalbumin family of serpin proteins. FEBS Lett. 315: 105-108.
37. Ritchie, H., Lawrie, L.C., Crombie, P.W., Mosesson, M.W., and Booth, N.A. 2000. Cross-linking of plasminogen activator inhibitor 2 and α 2-antiplasmin to fibrin(ogen). J. Biol. Chem. 275: 24915-24920.
38. Rogers, D.R. 1965. Screening for amyloid with the Thioflavin-T fluorescent method. Am. J. Clin. Pathol. 44: 59-61.
39. Schick, C., Pemberton, P.A., Shi, G.P., Kamachi, Y., Cataltepe, S., Bartuski, A.J., Gornstein, E.R., Bromme, D., Chapman, H.A., and Silverman, G.A. 1998. Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: A kinetic analysis. Biochemistry 37: 5258-5266.
40. Scott, F.L., Hirst, C.E., Sun, J., Bird, C.H., Bottomley, S.P., and Bird, P.I. 1999. The intracellular serpin proteinase inhibitor 6 is expressed in monocytes and granulocytes and is a potent inhibitor of the azurophilic granule protease, cathepsin G. Blood 93: 2089-2097.
41. Sheng, S., Pemberton, P.A., and Sager, R. 1994. Production, purification, and characterization of recombinant maspin proteins. J. Biol. Chem. 269: 30988-30993.
42. Sheng, S., Carey, J., Seftor, E.A., Dias, L., Hendrix, M.J., and Sager, R. 1996. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. 93: 11669-11674.
43. Silverman, G.A., Bird, P.I., Carrell, R.W., Church, F.C., Coughlin, P.B., Gettins, P.G., Irving, J.A., Lomas, D.A., Luke, C.J., Moyer, R.W., et al. 2001. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276: 33293-33296.
44. Sivasothy, P., Dafforn, T.R., Gettins, P.G., and Lomas, D.A. 2000. Pathogenic α 1-antitrypsin polymers are formed by reactive loop-β-sheet A linkage. J. Biol. Chem. 275: 33663-33668.
45. Sproule, B.J., Cox, D.W., Hsu, K., Salkie, M.L., and Herbert, F.A. 1983. Pulmonary function associated with the Mmalton deficient variant of α 1-antitrypsin. Ant. Rev. Respir Dis. 127: 237-240.
46. Stein, P.E. and Carrell, R.W. 1995. What do dysfunctional serpins tell us about molecular mobility and disease? Nat. Struct. Biol. 2: 96-113.
47. Stein, P.E., Leslie, A.G., Finch, J.T., Turnell, W.G., McLaughlin, P.J., and Carrell, R.W. 1990. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature 347: 99-102.
48. Sun, J., Coughlin, P., Salem, H.H., and Bird, P. 1995. Production and characterization of recombinant human proteinase inhibitor 6 expressed in Pichia pastoris. Biochim. Biophys. Acta 1252: 28-34.
49. Sun, J., Bird, C.H., Sutton, V., McDonald, L., Coughlin, P.B., De Jong, T.A., Trapani, J.A., and Bird, P.I. 1996. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J. Biol. Chem. 271: 27802-27809.
50. Takabe, K., Seyama, K., Shinada, H., Nouchi, T., Miyahara, Y., Nukiwa, T., Miyake, K., Tsukimoto, K., Ichioka, M., and Marumo, F. 1992. A new variant of α-1-antitrypsin deficiency (Siiyama) associated with pulmonary emphysema. Intern. Med. 31: 702-707.
51. Tew, D.J. and Bottomley, S.P. 2001. Intrinsic fluorescence changes and rapid kinetics of proteinase deformation during serpin inhibition. FEBS Lett. 494: 30-33.
52. Wilczynska, M., Lobov, S., Ohlsson, P.I., and Ny, T. 2003. A redox-sensitive loop regulates plasminogen activator inhibitor type 2 (PAI-2) polymerization. EMBO J. 22: 1753-1761.
53. Zhang, M., Volpert, O., Shi, Y.H., and Bouck, N. 2000. Maspin is an angiogenesis inhibitor. Nat. Med. 6: 196-199.
54. Zhou, A., Faint, R., Charlton, P., Dafforn, T.R., Carrell, R.W., and Lomas, D.A. 2001. Polymerization of plasminogen activator inhibitor-1. J. Biol. Chem. 276: 9115-9122.
55. Zou, Z., Anisowicz, A., Hendrix, M.J., Thor, A., Neveu, M., Sheng, S., Rafidi, K., Seftor, E., and Sager, R. 1994. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263: 526-529.